Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

3TR

Financiado

Cerrado

Identification of the Molecular Mechanisms of non response to Treatments Relaps...

Identification of the Molecular Mechanisms of non response to Treatments Relapses and Remission in Autoimmune Inflammatory and Allergic Conditions 3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions, SMEs, and 8 major pharmaceutical companies, teamed to study a fundamental issue in medic... ver más

31/08/2026

FUNDACION PUBLICA...

88M€

Presupuesto del proyecto: 88M€

Líder del proyecto

FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 14M€

Fecha límite participación Sin fecha límite de participación.

Ver 86 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-08-22

IMI2-2018-14-01: Targeted immune intervention for th...

I+D

Cerrada hace 6 años

0% 46% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

86 Participantes

FUNDACION PUBLICA ANDALUZA P...

9.47M€ | Lider

ADVANCED WAVE SENSORS

250.00K€ | Participante

BRISTOL-MYERS SQUIBB COMPANY...

JANSSEN PHARMACEUTICA NV

5.03M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2011-27370 IDENTIFICATION OF NEW TARGETS TO MODULATE CHEMOKINE FUNCTION... 242K€ Cerrado

BIOVACSAFE Biomarkers For Enhanced Vaccine Safety 31M€ Cerrado

PCIN-2017-093 ANTICUERPOS ANTI-FARMACOS Y DETECCION MOLECULAR DE FARMACOS... 121K€ Cerrado

PTQ-14-06856 Identificación, desarrollo y validación clínica de un sistem... 50K€ Cerrado

TranSYS Translational SYStemics Personalised Medicine at the Interf... 4M€ Cerrado

INFLANET Training European Experts in Inflammation from the molecula... 4M€ Cerrado

Duración del proyecto: 84 meses Fecha Inicio: 2019-08-22
Fecha Fin: 2026-08-31

Líder del proyecto

FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 14M€

Presupuesto del proyecto 88M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto 3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions, SMEs, and 8 major pharmaceutical companies, teamed to study a fundamental issue in medicine: the mechanisms of response and non-response to therapies, the major aim of 3TR, both within single disease entities and across diseases, where molecular stratification may identify shared disease taxonomies. The molecular identification of groups of patients to whom a drug will benefit, will allow focusing on those who are drug orphan. Harmonization of data from existing academy or industry-sponsored studies will identify biomarkers to inform a new collection. Specimens of diseased tissues, blood, stools, and other fluids will be obtained in a de novo observational prospective trial with standard of care medication prior, during and after first or second line of treatment. Because the studies will be at different phases of progression, a carrousel model of work was designed for input and output of data to be continuously analysed, and interpreted, to inform those measurements to be undertaken and allow cross-validation of results. The 3TR team will elucidate the role of the microbiome, genetics and regulatory genomic features in disease progression. The working aims of 3TR are: 1) establish a centralized data management platform; 2) perform comprehensive molecular and clinical characterisation of a prospective patient cohort; 3) establish integrated analysis of all data using advanced bioinformatics/statistical and modelling methods; 4) identify sets of predictive biomarkers of response/non-response to therapies; 5) improve the competitiveness of European industry and support development of novel solutions. 3TR will sustain beyond the project end the samples and its knowledge base. 3TR will challenge and revolutionize the conventional single-disease based approach with important implications in future disease treatment.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores